Opioid use has been reported to be associated with increased fracture risks. In a nested case-control study using the United Kingdom-based General Practice Research Database, we tested the hypotheses that fracture risk was associated with 1) an elevated risk of falls caused by the acute central nervous system effects of opioids including sedation and dizziness, and 2) osteoporosis caused by chronic opioid-induced hypogonadism. Among a cohort of adults aged 18-80 years without cancer who received ≥1 opioid prescription during 1990-2008, we selected cases with a first diagnosed fracture of the hip, humerus, or wrist; up to 4 controls, matched by age, sex, index date (date of the first diagnosed fracture), and general practice, were randomly selected for each case. Adjusted odds ratios and 95% confidence intervals were estimated by using conditional logistic regression. Current use of 1 prescription was associated with a strong risk of fracture (adjusted odds ratio = 2.70, 95% confidence interval: 2.34, 3.13). The risk decreased with increasing use. There was no association with current use of >20 opioid prescriptions. The findings were consistent for all study fractures and for most common opioids, suggesting that acute central nervous system effects of opioids rather than chronic opioid-induced hypogonadism play a key role in fracture risk.
Epidemiologic studies have reported increased fracture risks ranging from 1.4-to 5-fold in users of opioid analgesics. The observed risks are believed to be associated with a high risk of falls caused by the central nervous system effects of opioids, such as sedation and dizziness (1) (2) (3) (4) (5) (6) (7) (8) (9) . In addition, opioid-induced hypogonadism may cause osteoporosis, which could substantially contribute, directly or indirectly, to opioid-associated bone fractures (10) . Pedrazzoni et al. (11) observed a significant lower bone density in male chronic heroin users compared with healthy age-and sexmatched control subjects. Kim et al. (12) also reported low bone density in patients receiving methadone maintenance therapy.
There have been dramatic increases in the number of opioid prescriptions for chronic noncancer pain over the past decade in the United States, which is illustrated by an annual increase of 21% for extended-release opioids and 6% for immediate-release opioids from 2002 to 2009 (13) . Safety concerns have grown regarding the extensive use of opioids, including the risk of fracture as a consequence of opioidinduced hypogonadism (14) (15) (16) (17) . Nevertheless, no studies have been specifically designed to address this potential opioid-induced hypogonadism fracture risk. Also, some of the prior studies have been criticized for their inability to control adequately for confounders (18) , and all of them except 1 were restricted to elderly adults (5) . Thus, we conducted a nested case-control study to evaluate the association between opioid use and risk of fracture, particularly extensive opioid use, presumably through opioid-induced hypogonadism and potential subsequent osteoporosis.
data from more than 500 general physician practices in the United Kingdom since 1987. It covers approximately 5% of the United Kingdom's population and has a representative age/sex distribution. The information recorded includes patient demographics and characteristics, clinical diagnoses (coded with the Read code), drug prescriptions (coded with the Multilex coding system (First Databank, Ltd., Exeter, England)), consultant referrals, and hospitalizations. Validation studies have shown the high quality of recorded drug exposure and diagnoses (19) (20) (21) (22) , including diagnosis of fracture (23) . The study sample comprised 1.7 million noncancer patients who had a record of at least 1 opioid prescription (Web Table 1 , available at http://aje.oxfordjournals.org/) between January 1, 1990, and December 31, 2008 , in the General Practice Research Database. This criterion was designed to limit the effects of the indication for opioids on the development of fracture and also to optimize the exposure prevalence in the study sample, thus ensuring an efficient ratio of exposed to unexposed individuals. In the study sample, approximately 70% were defined as new opioid users; that is, they had at least 1 year of opioid-free recorded medical history before the date of the first documented opioid prescription. This study was reviewed and approved by the Independent Scientific Advisory Committee for the United Kingdom Medicines and Healthcare Products Regulatory Agency. From the study sample, we identified all cases with a firsttime diagnosed fracture of the hip, humerus, or wrist during 1990-2008. These fracture types were selected because they typically occur as low-energy trauma fractures in older subjects with low bone density (24) . We did not include fractures of the spine because it was often impossible to distinguish incident from existing vertebral fracture (25) . All cases were required to be aged 18-80 years and to have at least 2 years of medical history before the index date (i.e., the date of the first diagnosis of fracture). We excluded patients with any Read code indicating a history of cancer (except nonmelanoma skin cancer), dementia, metabolic bone disease, Cushing syndrome, hyperparathyroidism, long-term immobilization, or alcohol or drug abuse at any time before the index date. We also excluded those with a history of any fracture within 2 years before the index date and those with motor vehicle accidents recorded within 90 days before or on the index date. Because osteoporosis is an important risk factor for fracture and is also in the hypothesized causal pathway between the effects of extensive opioid use and the risk of fracture, we excluded patients who had histories of osteoporosis before the dates of their first documented opioid prescriptions. However, people who developed osteoporosis after receipt of their first opioid prescriptions were included.
Control selection
From the study sample, we randomly selected up to 4 controls for each eligible case via risk-set sampling (26) , matched on age (same year of birth), sex, index date, and general practice. The same inclusion and exclusion criteria that we applied to cases were applied to controls.
Opioid exposure
We identified all opioid prescriptions in the computer record before (not on or after) the index date for cases and controls without knowledge of disease status. We defined "current use" as a prescription with a supply that lasted up to or within 30 days before the index date, "recent use" as a prescription with a supply that ended within 31-90 days before the index date, and "past use" as a prescription with a supply that ended within 91-365 days before the index date. We defined "nonuse" (reference) as those with either no recorded opioid prescriptions at any time before the index date or 1 or more opioid prescriptions that ended more than 1 year before the index date. For "current users," we further evaluated the effects of cumulative use defined as the number of opioid prescriptions recorded before the index date and categorized as 1, 2-3, 4-5, 6-20, 21-50, 51-100, or >100 prescriptions. Prescription categories were defined to examine the potential effect of different amounts of cumulative use. Note that we did not restrict cumulative use to prescriptions recorded within 2 years before the index date because we intended to estimate the potential maximum effect of extensive opioid use. "Current use" was also analyzed according to the last opioid type prescribed before the index date. If different types of opioids were prescribed simultaneously or if the supply of a second opioid overlapped the last opioid prescription, use was classified as polytherapy.
Covariates
We collected many covariates, including lifestyle risk factors, comorbidities, comedications, and types of pain, which are risk factors associated with either fracture or frailty. These are listed in Table 1 .
Statistical analysis
We conducted conditional logistic regression analyses to estimate the multivariate adjusted odds ratios of overall fracture and of specific fracture sites and 95% confidence intervals among those with opioid exposure compared with those without. We evaluated each covariate for potential confounding by separately evaluating the associations with fracture and opioid exposure and then examining the strength of potential confounding by assessing the effect of each confounder on the crude association between opioid exposure and fracture, 1 confounder at a time. None of the covariates affected the crude association of opioid exposure and the risk of fracture by 10% or more. Despite this, we retained all confounders that were associated with both opioid exposure and fracture, because each of them made a small but non-0 contribution to the association of opioid exposure with fracture. We also controlled for new versus prevalent opioid use in the analyses to minimize the impact of including prevalent users. To examine whether age and sex were effect modifiers, we constructed multivariate models that included interaction terms for each variable separately with cumulative opioid use. Then we conducted stratified analyses to examine whether the associations between each category of cumulative use and fracture were homogeneous across age groups (18-60, 61-70, and 71-80 years) among men and women separately.
We performed 4 sensitivity analyses to examine whether the primary findings were robust. First, we performed a duration analysis for current users that categorized the time from the first recorded opioid prescription to the index date. Second, we repeated the analyses restricted to the sets where both cases and matched controls were new opioid users. Third, to estimate the impact of different lengths of medical history recorded before the index date among cases and controls, we repeated analyses restricted to the sets where both cases and matched controls had the same length of medical history. Finally, we conducted stratified analyses to examine whether the associations between each category of cumulative opioid use and fracture were homogeneous across different lengths of medical history recorded before the index date (<5, 5-10, and >10 years) and calendar year of the index date (1990-1994, 1995-1999, 2000-2004, and 2005-2008 ).
All analyses were conducted by using SAS, version 9.2, software (SAS Institute Inc., Cary, North Carolina).
RESULTS
We identified 21,739 eligible fracture cases to whom we matched 85,326 controls. Among the cases hip, humerus, and wrist fractures accounted for 23.5%, 25.4%, and 51.1%, respectively. Cases had a mean age of 62 years, and 76.6% were women. Cases and controls had a similar distribution of length of medical history before the index date (mean = 8 years). Compared with controls, cases were less likely to have a body mass index (weight (kg)/height (m) 2 ) ≥25 (39.3% vs. 45.4%), but were more likely to have general practice visits within 2 years before the index date (mean = 31 vs. 28 visits). Cases generally had more comorbidities than did controls. Cases were also more likely than controls to take concomitant medications, such as steroids and antidepressants, but were less likely to have hormone replacement therapy (Table 1) .
After adjustment for all covariates associated with both opioid exposure and risk of fracture as well as new versus prevalent opioid use, the risk of fracture for current opioid users remained marginally higher compared with nonusers (adjusted odds ratio = 1.27, 95% confidence interval: 1.21, 1.33), whereas there was no increased risk for recent or past users. Current opioid users consistently had marginally increased risks for hip, humerus, and wrist fractures ( Table 2) .
Compared with nonusers, current opioid users who had received 1 prescription had a strong increased risk of fracture (adjusted odds ratio = 2.70, 95% confidence interval: 2.34, 3.13). The fracture risk decreased with increasing use, with a pronounced reduction among those with cumulative use of 6-20 prescriptions (adjusted odds ratio = 1.17, 95% confidence interval: 1.08, 1.27). There was no increased risk for those with >20 prescriptions (Table 3) . The results of cumulative opioid use were similar for hip, humerus, or wrist fractures (Figure 1) .
Among current users, people exposed to morphine or polytherapy had adjusted odds ratios of 1.62 and 1.70, respectively, 2 ), number of general practice visits, recorded years before index date, opioid use (new vs. prevalent), comorbidities (including osteoporosis, osteoarthritis, rheumatoid arthritis, fibromyalgia, Parkinson disease, multiple sclerosis, chronic obstructive pulmonary disease, ischemic heart disease, congestive heart failure, stroke, and cataract), comedications (including antiosteoporosis drugs, steroids, hormone replacement therapy, antidepressants, antiepileptics, hypnotics and anxiolytics, acetaminophen, antihypertensive drugs, and calcium), and types of pain (including headache, joint pain, and other musculoskeletal pain) in addition to matching variables.
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Am J Epidemiol. 2013;178(4):559-569 whereas those exposed to dihydrocodeine, codeine, tramadol, or propoxyphene had adjusted odds ratios ranging from 1.20 to 1.38; use of buprenorphine yielded no increased risk of fracture (adjusted odds ratio = 1.03, 95% confidence interval: 0.59, 1.79). The results of each opioid type except morphine were similar for hip, humerus, or wrist fractures (Figure 2 ). When we further evaluated the fracture risk by cumulative use for current users of dihydrocodeine, codeine, tramadol, and propoxyphene, which were the most common opioid types in the study, we found that those with 1 prescription consistently had the strongest fracture risk with adjusted odds ratios ranging from 2.27 for codeine to 5.49 for tramadol, and the risk decreased with increasing use. It should be noted that current use of >100 prescriptions for propoxyphene was associated with a small increased fracture risk (adjusted odds ratio = 1.42, 95% confidence interval: 1.13, 1.77), which was not present for dihydrocodeine, codeine, or tramadol (Web Figure 1) .
We did not find statistically significant interactions with sex or age and cumulative opioid use (P = 0.20 and P = 0.22, ), number of general practice visits, recorded years before index date, opioid use (new vs. prevalent), comorbidities (including osteoporosis, osteoarthritis, rheumatoid arthritis, fibromyalgia, Parkinson disease, multiple sclerosis, chronic obstructive pulmonary disease, ischemic heart disease, congestive heart failure, stroke, and cataract), comedications (including antiosteoporosis drugs, steroids, hormone replacement therapy, antidepressants, antiepileptics, hypnotics and anxiolytics, acetaminophen, antihypertensive drugs, and calcium), types of pain (including headache, joint pain, and other musculoskeletal pain), and recent/past opioid use in addition to matching variables. ), number of general practice visits, recorded years before index date, opioid use (new vs. prevalent), comorbidities (including osteoporosis, osteoarthritis, rheumatoid arthritis, fibromyalgia, Parkinson disease, multiple sclerosis, chronic obstructive pulmonary disease, ischemic heart disease, congestive heart failure, stroke, and cataract), comedications (including antiosteoporosis drugs, steroids, hormone replacement therapy, antidepressants, antiepileptics, hypnotics and anxiolytics, acetaminophen, antihypertensive drugs, and calcium), types of pain (including headache, joint pain, and other musculoskeletal pain), and recent/past opioid use in addition to matching variables. Bars, confidence interval. respectively). When we examined the effects of cumulative use stratified on both sex and age, we again found results similar to those of all fractures, though men aged 18-60 years with the highest cumulative use (i.e., exposed to >100 opioid prescriptions) had an increased risk for fracture (adjusted odds ratio = 2.13, 95% confidence interval: 1.18, 3.82) (Figure 3) .
From the duration analysis, we found current opioid users with the shortest duration (1-15 days) had a 3.09-fold fracture risk (95% confidence interval: 2.64, 3.62) compared with nonusers, and the risk decreased with increasing duration of use, which was consistent with the effects of current cumulative use. The results of cumulative use restricted to new opioid users were not substantially changed. Similarly, the results that were restricted to cases and matched controls who had the same length of medical history before the index date were not substantially changed. Stratification either by the length of medical history recorded before the index date or by calendar year of the index date yielded similar effects of cumulative use on risk of fracture in each stratum.
DISCUSSION
In this study, a clear dose-response relationship between current cumulative opioid use and the risk of fracture was observed. Current light cumulative use (≤5 opioid prescriptions) ), number of general practice visits, recorded years before index date, opioid use (new vs. prevalent), comorbidities (including osteoporosis, osteoarthritis, rheumatoid arthritis, fibromyalgia, Parkinson disease, multiple sclerosis, chronic obstructive pulmonary disease, ischemic heart disease, congestive heart failure, stroke, and cataract), comedications (including antiosteoporosis drugs, steroids, hormone replacement therapy, antidepressants, antiepileptics, hypnotics and anxiolytics, acetaminophen, antihypertensive drugs, and calcium), types of pain (including headache, joint pain, and other musculoskeletal pain), and recent/past opioid use in addition to matching variables. Bars, confidence interval.
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Am J Epidemiol. 2013;178(4):559-569 was associated with increased fracture risk compared with nonuse, particularly current use with 1 opioid prescription (equivalently an average of 16 days), which was associated with an almost 3-fold fracture risk. The risk rapidly decreased with increasing use. There was no increased risk of fracture associated with current heavy cumulative use (>20 opioid prescriptions) or with opioid use that ended more than 30 days before the fracture diagnosis. The findings were consistent for all fracture types and for the most common opioid analgesics.
There are at least 2 mechanisms to explain the increased fracture risk among opioid users. One is that there is a risk of falls caused by the central nervous system effects of opioids, and the other is an effect on bone metabolism through opioid-induced hypogonadism (10) . The central nervous system effects of opioids most frequently occur at initiation of opioid therapy or when a significant dose increase occurs. The associated symptoms frequently resolve after a few days, although central nervous system effects can persist in people with comorbidities such as dementia or in those who receive other sedating medications (27) . Decreased plasma testosterone levels have long been documented in men who are addicted to narcotics (28) (29) (30) . Now, similar hormonal changes to both testosterone and estrogen levels have been observed in those taking opioids for chronic noncancer pain (31) (32) (33) (34) (35) (36) (37) . Our findings for current cumulative use support the first mechanism, suggesting that the central nervous system effects of opioids in the initial period play a key role in the fracture risk, and tolerance to these side effects develops with extended use.
Although there does not seem to be an effect of heavy opioid use in these data, we cannot rule out the possibility that the fracture risk through hypogonadism may be linked to specific opioids. Recently, Rubinstein et al. (38) reported that men taking long-acting opioids had approximately ), number of general practictioner visits, recorded years before index date, opioid use (new vs. prevalent), comorbidities (including osteoporosis, osteoarthritis, rheumatoid arthritis, fibromyalgia, Parkinson disease, multiple sclerosis, chronic obstructive pulmonary disease, ischemic heart disease, congestive heart failure, stroke, and cataract), comedications (including antiosteoporosis drugs, steroids, hormone replacement therapy, antidepressants, antiepileptics, hypnotics and anxiolytics, acetaminophen, antihypertensive drugs, and calcium), types of pain (including headache, joint pain, and other musculoskeletal pain), and recent/ past opioid use in addition to matching variables. Bars, confidence interval.
5-fold greater odds of becoming hypogonadal compared with men taking short-acting opioids. If this finding is real, we would likely have missed the effect because, though our study included a wide range of opioids, we had limited information on long-acting opioids, such as extended-release morphine. We did find a 1.4-fold increased risk in those who were current cumulative users of >100 prescriptions for propoxyphene, but not for other types. Propoxyphene, however, was banned in the United Kingdom in 2005 (39) and recently removed from the US market because of concerns regarding risk of fatal heart rhythm abnormalities (40) , so whether porpoxyphene is more likely to induce hypogonadism compared with other opioid types can no longer be studied. However, the fact that, like methadone, propoxyphene has a potential for dose-stacking because of its own and its metabolite's prolonged half-lives (41) adds some credence to the possibility that long-acting opioids induce hypogonadism.
We also cannot rule out the possibility that opioidinduced hypogonadism may play a role in the fracture risk in a specific population; we found that current cumulative use of >100 prescriptions was significantly associated with an increased fracture risk in men aged 60 years or younger, but not in men over age 60 years and not in women of any age. Fraser et al. (37) observed a lower prevalence of hypogonadism in women compared with men on opioid therapy, and Grey et al. (42) reported decreased bone density in men on methadone maintenance therapy, but not in women. If there is a sex difference in the effect of the heaviest opioid use, it might at least partly explain this finding. Another possibility is related to muscle deconditioning, which can occur when chronic pain patients become sedentary. If opioid therapy improves patients' function through alleviation of chronic pain, these patients may become more active and thus have more opportunities to fall and subsequently to have a fracture. In this instance, the sex and age difference in the effect of current cumulative use at the highest level may reflect behavior differences by sex and age. It is also possible that the increased risk was a chance finding due to limited data on young male heavy users, which was reflected in the wide confidence intervals.
The relationship between opioid analgesics and fractures is not a new finding (1-9). Despite varying magnitudes of effect, previous studies consistently reported increased fracture risks. However, none of them examined cumulative opioid use in relationship to the risk of fracture. Our study was designed to evaluate acute and chronic effects of opioids by examining cumulative use, which distinguished this study from the existing studies. Also of importance, by using the General Practice Research Database, we obtained data on a large number of subjects with heavy opioid use and thus could efficiently evaluate their potential effect on bone metabolism. Our study included subjects aged 18-80 years, which added valuable information on the use of opioids in young adults.
Despite these strengths, the observations should be interpreted in light of several potential limitations. First, we did not restrict all study subjects to new opioid users because extensive opioid use was more likely to occur in prevalent users. However, we controlled for new versus prevalent opioid use as a covariate in the analyses to minimize the impact of including prevalent users on the effects of current cumulative use. Furthermore, we repeated the analyses restricted to new opioid users, who accounted for most of the study subjects, and found little change in the results.
Second, some misclassification of opioid exposure may exist. Both codeine and dihydrocodeine in combination with paracetamol are available over the counter in the United Kingdom, so there is a possibility that some use of these drugs may not have been captured in the data. However, this is unlikely to have much impact on heavy users, because people who receive more than minimal analgesia tend to receive prescriptions from their general practitioners to avoid paying out of pocket. In this circumstance, the estimates for current light cumulative use were the most likely to be underestimated, because this misclassification is likely to be nondifferential, which typically biases relative risk estimates toward the null. It is also possible that those who abuse or are addicted to prescription opioids may seek illegal sources for additional opioids, which would not be captured in the General Practice Research Database. To minimize the impact of misclassification of exposure due to potential illegal opioid use, we excluded subjects with a recorded history of alcohol and/or drug abuse, which are strong predictors of opioid misuse in chronic pain patients (43), though they likely underrepresent the total number of prescription opioid abusers. Missing information on illegally obtained opioids would not, however, explain these results, particularly for current light cumulative users who are unlikely to become prescription opioid abusers. It is possible that opioids were used to treat pain preceding the actual fracture diagnosis. However, when we checked a random sample of fracture cases with current light opioid use, the main indications (80%) for opioids were back pain, knee pain, and other nonfracturerelated pain. Also, some fractures were serious and would not have been missed. Therefore, although there may be some slight overestimation of the odds ratios for current light use, misclassification of exposure could not completely explain these results.
Finally, despite the fact that we collected information on many confounders, there is the possibility that residual confounding was present in the main analysis from uncollected confounders such as physical activity, bone density, and unmeasured differences in functional status across exposure groups. Nevertheless, it is unlikely that residual confounding could completely account for such a strong effect for current light cumulative use of opioids. Although varying lengths of medical history recorded before the index date between cases and controls may contribute to different available confounder information, we controlled for the length of medical history in analyses to minimize this potential confounding. Furthermore, there were no material changes in the results when we restricted the analyses to cases and matched controls who had the same length of medical history recorded before the index date. Nor did the results differ in the analyses stratified on length of medical history. In addition, because we controlled for osteoporosis, which is in the hypothesized causal pathway between extensive opioid use and risk of fracture, it is also possible that the odds ratios for extensive opioid use were underestimated (44) . However, when we repeated the analyses without controlling for osteoporosis, the results did not materially change.
These findings indicate that current light use of opioids increases the risk of fractures in adults with noncancer pain, particularly in the initial weeks of use. We also found reassuring evidence that extensive opioid use is not associated with an increased risk of fracture, particularly in women, though we cannot rule out the possibility that fracture risk through opioid-induced hypogonadism may be linked to specific opioids or may occur in young male patients.
